Skip to main content

Table 1 Characteristics of patients with HCC according to treatment modalities

From: Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study

   Sandostatin LAR TACE multimodal therapy palliative care
   BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B
number   11 14 5 9 7 10 17 22
Sex          
  male 6 10 4 8 7 9 14 16
  female 5 4 1 1 0 1 3 6
liver cirrhosis          
  no 0 0 0 2 1 0 2 2
  yes 11 14 5 7 6 10 15 20
Child-Pugh-classification          
  Child A 9 12 1 3 5 8 7 7
  Child B 2 2 4 4 1 2 8 13
  Child C 0 0 0 0 0 0 0 0
MELD (median/range)   7.33 (0.27-15.98) 7.61 (0.16-15.0) 14.60 (11.13-17.35) 11.46 (6.68-16.90) 11.56 (6.78-49.26) 8.98 (7.15-16.01) 12.31 (4.66-58.20) 13.20 (1.53-49.82)
Etiology          
  Alcoholism 5 8 2 4 5 3 8 8
  chronic hepatitis B 1 0 0 0 1 0 2 0
  chronic hepatitis C 4 4 3 2 1 7 5 7
  others 1 2 0 3 0 0 2 6
Age (median/range)   66.5 (53.7-80.5) 68.7 (49.4-73.4) 64.9 (63.6-69.2) 68.4 (48.4-78.4) 50.5 (47.4-64.6) 69.9 (61.2-76.9) 68.5 (43.1-81.2) 62.5 (44.8-73.4)